Bień Ewa, Balcerska Anna, Ciesielski Dominik
Kliniki Pediatrii, Hematologii, Onkologii i Endokrynologii oraz, Akademii Medycznej w Gdańsku.
Wiad Lek. 2006;59(1-2):10-5.
The significance of sIL-2R as a marker of pediatric malignancies activity has not been evaluated so far. The aim of the study was to determine the clinical role of sIL-2R in diagnostics and prognosis in children with neoplasms.
The study included 61 children (F/M: 28/33, mean age 7.9 years) diagnosed with acute leukemias (ALL - 22, ANLL - 3), malignant lymphomas (HD - 12, NHL - 6), nephroblastoma and soft tissue sarcomas (Tu Wilms -10, SA- 8). Control group consisted of 30 healthy children (F/M: 15/15, mean age 8.8 years). Serum sIL-2R was measured by ELISA (DAKO, the Netherlands).
Correlation of sIL-2R with age was stated thus the results have been presented as multiplication of the upper normal range (> 1 xN) determined for the patient's age at time of samples collection. Pre-treatment levels of sIL-2R in cancer patients were elevated as compared to controls, both regarding the whole oncological group and its subgroups: A (ALL + ANLL + NHL), B (HD) and C (Tu Wilms + SA) (p < 0.001). 92% of cancer patients presented with elevated levels of sIL-2R compared to 0% in healthy controls. sIL-2R levels were significantly higher in advanced stages of solid tumours and lymphomas and in children with HD and NHL with general symptoms and bulky disease presentation. The pre-treatment levels of sIL-2R proved to have a great predictive value for overall survival.
sIL-2R determination may serve as a useful marker of diagnostics and prognosis in different histological types of pediatric malignancies.
可溶性白细胞介素-2受体（sIL-2R）作为小儿恶性肿瘤活动标志物的意义迄今尚未得到评估。本研究的目的是确定sIL-2R在儿童肿瘤诊断和预后中的临床作用。
本研究纳入61例儿童（女/男：28/33，平均年龄7.9岁），诊断为急性白血病（急性淋巴细胞白血病-22例，急性非淋巴细胞白血病-3例）、恶性淋巴瘤（霍奇金淋巴瘤-12例，非霍奇金淋巴瘤-6例）、肾母细胞瘤和软组织肉瘤（威尔姆斯瘤-10例，肉瘤-8例）。对照组由30名健康儿童组成（女/男：15/15，平均年龄8.8岁）。采用酶联免疫吸附测定法（ELISA，荷兰达科公司）检测血清sIL-2R。
sIL-2R与年龄的相关性已明确，因此结果以样本采集时患者年龄对应的正常范围上限（＞1×N）的倍数表示。与对照组相比，癌症患者治疗前的sIL-2R水平升高，无论是整个肿瘤组还是其亚组：A组（急性淋巴细胞白血病+急性非淋巴细胞白血病+非霍奇金淋巴瘤）、B组（霍奇金淋巴瘤）和C组（威尔姆斯瘤+肉瘤）（p＜0.001）。与健康对照组的0%相比，92%的癌症患者sIL-2R水平升高。实体瘤和淋巴瘤晚期以及有全身症状和肿块性病变的霍奇金淋巴瘤和非霍奇金淋巴瘤患儿的sIL-2R水平显著更高。治疗前的sIL-2R水平对总生存期具有很大的预测价值。
sIL-2R测定可作为不同组织学类型小儿恶性肿瘤诊断和预后的有用标志物。
